×
0 0 -0.00763358778625955 -0.00763358778625955 -0.0343511450381679 -0.00763358778625955 -0.0648473282442749 -0.122137404580153
Stockreport

Akari completes mid-stage study of Coversin in PNH; shares up 13% premarket [Seeking Alpha]

AKARI THERAPEUTICS PLC ADR (AKTX)  More Company Research Source: Seeking Alpha
US:NASDAQ Investor Relations: investor.akaritx.com/investor-relations
PDF Akari completes mid-stage study of Coversin in PNH; shares up 13% premarketThinly traded nano cap Akari Therapeutics (NASDAQ:AKTX) is up13% premarket on light volume in response to itsannouncement of final results from an eight-subject 90-day open-label Phase 2 clinical trial, COBALT, evaluating lead candidate Coversin in patients with paroxysmal nocturnal hemoglobinuria (PNH).As previously reported, the study met its primary endpoint. Seven of the eight participants completed the trial and all are enrolled in CONSERVE, a long-term safety study.A Phase 3 trial, CAPSTONE, in PNH patients who have not been previously treated with a complement inhibitor (e.g., Alexion's Soliris) should commence in late March.A Phase 2 study assessing Coversin in atypical Hemolytic Uremic Syndrome (aHUS) has been initiated.Coversin is a second-generation complement inhibitor.Previously:Akari's Coversin successful in mid-stage PNH study (Dec. 8, 2017)See all stocks on the move »Now read:Achillion Pharmaceu [Read more]

IMPACT SNAPSHOT EVENT TIME: AKTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS